Małgorzata Ułańska

1.1k total citations
8 papers, 106 citations indexed

About

Małgorzata Ułańska is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, Małgorzata Ułańska has authored 8 papers receiving a total of 106 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 3 papers in Pulmonary and Respiratory Medicine and 2 papers in Genetics. Recurrent topics in Małgorzata Ułańska's work include Advanced Breast Cancer Therapies (3 papers), HER2/EGFR in Cancer Research (3 papers) and Chronic Lymphocytic Leukemia Research (2 papers). Małgorzata Ułańska is often cited by papers focused on Advanced Breast Cancer Therapies (3 papers), HER2/EGFR in Cancer Research (3 papers) and Chronic Lymphocytic Leukemia Research (2 papers). Małgorzata Ułańska collaborates with scholars based in Poland, Spain and Croatia. Małgorzata Ułańska's co-authors include Marta Pabianek, Witold Owczarek, Magdalena Ciążyńska, Aleksandra Lesiak, Joanna Narbutt, Katarzyna Szczepaniak, Małgorzata Skibińska, Bradford E. Jackson, Lida A. Mina and Steven W. Papish and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

Małgorzata Ułańska

8 papers receiving 104 citations

Peers

Małgorzata Ułańska

ONCOL

CP

PRM

PHEOH

MB

Snezhana Smichkoska North Macedonia

Jennifer Vaughn United States

Claire Brock United Kingdom

Ellen M Goldberg United States

Rohini Sen United States

Rebecca Mottram United Kingdom

Azizah Ab Manan Malaysia

L Polácek United States

Ethna McFerran United Kingdom

Nektaria Alexandri Germany

Snezhana Smichkoska North Macedonia

Małgorzata Ułańska

60 ×0.8

ONCOL

29 ×1.1

CP

20 ×1.2

PRM

7 ×0.4

PHEOH

8 ×0.7

MB

Citations per year, relative to Małgorzata Ułańska Małgorzata Ułańska (= 1×) peers Snezhana Smichkoska

Countries citing papers authored by Małgorzata Ułańska

Since Specialization

Citations

This map shows the geographic impact of Małgorzata Ułańska's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Małgorzata Ułańska with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Małgorzata Ułańska more than expected).

Fields of papers citing papers by Małgorzata Ułańska

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Małgorzata Ułańska. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Małgorzata Ułańska. The network helps show where Małgorzata Ułańska may publish in the future.

Co-authorship network of co-authors of Małgorzata Ułańska

This figure shows the co-authorship network connecting the top 25 collaborators of Małgorzata Ułańska. A scholar is included among the top collaborators of Małgorzata Ułańska based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Małgorzata Ułańska. Małgorzata Ułańska is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

1.

Freyer, Gilles, Noelia Martínez-Jáñez, Bożena Kukiełka-Budny, et al.. (2024). Single-agent metronomic versus weekly oral vinorelbine as first-line chemotherapy in patients with HR-positive/HER2-negative advanced breast cancer: The randomized Tempo Breast study. The Breast. 74. 103681–103681. 1 indexed citations

2.

Papish, Steven W., et al.. (2021). 564TiP A phase Ib dose-escalation study of ZN-c5, an oral selective estrogen receptor degrader (SERD), in combination with abemaciclib in patients with advanced estrogen receptor (ER)+/HER2- breast cancer. Annals of Oncology. 32. S618–S619. 12 indexed citations

3.

Cerić, Timur, Marko Jakopović, Santiago Ponce Aix, et al.. (2021). 1654P A phase Ib/II study of the dual MDMX/MDM2 inhibitor, ALRN-6924, for the prevention of chemotherapy-induced myelosuppression. Annals of Oncology. 32. S1166–S1166. 2 indexed citations

4.

Ciążyńska, Magdalena, Katarzyna Szczepaniak, Marta Pabianek, et al.. (2020). Primary Merkel Cell Carcinoma: A Retrospective Analysis of 31 Cases in Poland. Dermatology and Therapy. 10(5). 1003–1012. 3 indexed citations

5.

Ciążyńska, Magdalena, Marta Pabianek, Katarzyna Szczepaniak, et al.. (2020). Quality of life of cancer patients during coronavirus disease (COVID‐19) pandemic. Psycho-Oncology. 29(9). 1377–1379. 75 indexed citations

6.

Andrić, Zoran, Timur Cerić, Marko Jakopović, et al.. (2020). Prevention of Chemotherapy-induced Myelosuppression in SCLC patients treated with the Dual MDMX/MDM2 Inhibitor ALRN-6924. European Journal of Cancer. 138. S5–S5. 1 indexed citations

7.

Kusińska, Renata, Janusz Piekarski, Andrzej Kulig, et al.. (2015). Prognostic value of HER3, PTEN and p-HER2 expression in patients with HER2positive breast cancer.. PubMed. 69. 586–97. 10 indexed citations

8.

Ułańska, Małgorzata, et al.. (2005). Phase II study of vinorelbine (VRL) alternating i.v. and oral in combination with docetaxel (DTX) as 1^st line chemotherapy (CT) of metastatic breast cancer (MBC). Journal of Clinical Oncology. 23(16_suppl). 783–783. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact